title: Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan.
authors.forename: Monica A
authors.initials: MA
authors.lastname: Konerman
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan.
authors.forename: Anna S
authors.initials: AS
authors.lastname: Lok
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D003362:Cost-Benefit Analysis; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha